Nanobiotix Partners with Janssen to Co-develop and Commercialize Groundbreaking Radioenhancer, NBTXR3

NANOBIOTIX strikes an agreement to co-develop and commercialize an innovative radio enhancer (NBTXR3), which would be the first of its kind. Nanobiotix is a biotech company that focuses on physics-based solutions and treatments for cancer. Their new focus is on the development of Radio enhancers, which make tumor cells more responsive to radiotherapy. The agreement was with Janssen Pharmaceuticals of Johnson & Johnson. 

Related articles: Merger Announced Between Immunome and Morphimmune

Advancing Treatment Options for Solid Tumors and Metastatic Cancers

NBTXR3 is currently being evaluated in various studies focusing on solid tumors. Including a Phase 3 study targeting locally advanced head and neck cancer. Additionally, NBTXR3 is being investigated for its potential as an important agent when combined with immune checkpoint inhibitors (anti-PD-1) for patients with metastatic cancers.

Under this agreement, Nanobiotix will collaborate with the Interventional Oncology R&D Unit at Johnson & Johnson. This will grant Janssen a global license for the development and commercialization of NBTXR3. The license is exclusive, except for territories already licensed to Nanobiotix’s partner, LianBio. The agreement includes a conference call hosted by Nanobiotix to discuss the partnership details.

Nanobiotix Secures Major Financial Support and Exciting Milestone Opportunities with Janssen

Nanobiotix will receive significant near-term financial and operational support valued at up to $60 million. This includes an upfront cash licensing fee of $30 million and regulatory and development support worth up to $30 million. Provided at the sole discretion of Janssen, for the NANORAY-312 study. Nanobiotix will retain operational control over NANORAY-312 and all other ongoing studies, as well as maintain responsibility for the manufacturing, clinical supply, and initial commercial supply of NBTXR3. Janssen will assume full responsibility for an initial Phase 2 study investigating NBTXR3 in patients with stage three lung cancer. They will have the option to take control of studies currently led by Nanobiotix.

In addition to the upfront payments, Nanobiotix stands to receive success-based payments of up to $1.8 billion related to development, regulatory milestones, and sales. The agreement also outlines the potential for additional success-based payments of up to $650 million for five new indications developed by Janssen at its sole discretion and up to $220 million per indication developed by Nanobiotix in alignment with Janssen.

Furthermore, Nanobiotix will receive tiered double-digit royalties based on the net sales of NBTXR3 following its commercialization.

In summary, the collaboration between Nanobiotix and Janssen holds great promise for the global advancement and commercialization of NBTXR3, to make a significant impact on the lives of cancer patients worldwide.

Author

GeneOnline Team